【摘要】 目的:探讨地西他滨治疗成人急性髓细胞白血病(acutemyeloid leukemia,AML)的临床疗效和安全性。方法:收集2009年8月—2010年10月在本科接受地西他滨治疗的15例AML患者(年龄>18岁)的临床资料,评价其疗效和不良反应。结果:15例患者中,完全缓解3例,部分缓解5例,总有效率为53.3%。在12例可行细胞遗传学评价的患者中,1例(8.3%)获得完全细胞遗传学缓解。中位总生存期为123d(27～509d),中位无复发生存期为70d(19～306d),中位反应持续时间为33d(11～176d)。Ⅳ级血液学不良反应发生率为93.3%,Ⅲ～Ⅳ级感染发生率为33.3%,无Ⅲ～Ⅳ级出血、恶心呕吐和肝功能损伤。早期死亡1例。结论:地西他滨可有效治疗成人急性髓细胞白血病,血液学不良反应较重,必须给予积极的支持治疗。更多还原

【Abstract】 Objective:To evaluate the clinical therapeutic effect and safety of decitabine in the treatment for adult acute myeloid leukemia(AML).Methods:Clinical information from 15 patients(>18 years) with adult AML were collected between August 2009 and October 2010.The therapeutic effect and side reactions of decitabine were evaluated.Results:Of the 15 patients,3 patients achieved complete remission(CR),five patients achieved partial remission(PR).The overall response rate was 53.3%.Of the 12 patients whose cytogenetic evaluation was accessible,one patient(8.3%) achieved complete cytogenetic remission.The median overall survival(OS) was 123 d(27-509 d),the median relapse-free survival(RFS) was 70 d(19-306 d),and the median duration of response was 33 d(11-176 d).The incidence rate of grade Ⅳ hematologic toxicity was 93.3%,and the incidence rate of grade Ⅲ-Ⅳ infection was 33.3%.No severe bleeding,nausea and vomiting and liver injury(grade Ⅲ-Ⅳ) were observed.Early death occurred in one patient.Conclusion:Decitabine can effectively treat adult AML with more severe hematologic toxicity,and it is necessary to give active supportive treatment.更多还原